Et fase 1-studie af PLN-101095 hos voksne med avancerede eller metastatiske solide tumorer
En fase 1a/1b multicenter, åben-label dosiseskalering/-udvidelsesundersøgelse til evaluering af sikkerhed, tolerabilitet, farmakokinetik og foreløbige beviser for antitumoraktivitet af PLN-101095 som monoterapi og i kombination med Pembrolizumab hos voksne deltagere med solid tumor eller metastasering Hvem har sygdomsprogression, mens de er på Pembrolizumab
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.
The study will consist of 2 main parts:
- Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
- Part 2: Dose-expansion cohorts using Simon's 2-stage design
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Pliant Therapeutics Medical Monitor
- Telefonnummer: clintrials@pliantrx.com
- E-mail: clintrials@pliantrx.com
Studiesteder
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06511
- Afsluttet
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Rekruttering
- Georgetown University Medical Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Winship Cancer Institute of Emory University
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Rekruttering
- South Texas Accelerated Research Therapeutics (START)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University Medicine
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New Jersey
-
East Brunswick, New Jersey, Forenede Stater, 08816
- Rekruttering
- START New Jersey
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New York
-
Lake Success, New York, Forenede Stater, 11042
- Rekruttering
- START New York Long Island LLC
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
North Carolina
-
Wilson, North Carolina, Forenede Stater, 27893
- Rekruttering
- Carolina Cancer Research Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Rekruttering
- Avera Medical Group
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tennessee Oncology
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Texas
-
Austin, Texas, Forenede Stater, 78758
- Rekruttering
- NEXT Austin
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- START Center for Clinical Research
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- University of Texas MD Anderson Cancer Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, Forenede Stater, 77054
- Rekruttering
- NEXT Houston
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- UT Health San Antonio's Mays Cancer Center
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Utah
-
West Valley City, Utah, Forenede Stater, 84119
- Rekruttering
- START Mountain Region
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Inova Schar Cancer Institute
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- NEXT Virginia
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Washington
-
Edmonds, Washington, Forenede Stater, 98026
- Rekruttering
- Swedish Cancer Institute Medical Oncology
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Spanien, 08023
- Rekruttering
- Hospital Universitari Quirónsalud (NEXT Barcelona)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanien, 08023
- Rekruttering
- START Barcelona - Hospital HM Nou Delfos
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron - VHIO
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
La Rioja
-
Logroño, La Rioja, Spanien, 26006
- Rekruttering
- START Center for Cancer Research - La Rioja
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Madrid
-
Madrid, Madrid, Spanien, 28040
- Rekruttering
- START Madrid - Hospital Universitario Fundación Jiménez Díaz
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Madrid, Madrid, Spanien, 28050
- Rekruttering
- START Madrid - Centro Integral Oncológico Clara Campal
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Pozuelo de Alarcón
-
Madrid, Pozuelo de Alarcón, Spanien, 28223
- Rekruttering
- University Hospital Quironsalud Madrid (NEXT Madrid)
-
Kontakt:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Has histologically or cytologically confirmed advanced or metastatic solid tumor
- Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
- Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
- Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
- At least 1 measurable lesion, as defined by RECIST v1.1
- Estimated survival of ≥3 months
- Have adequate bone marrow and organ function.
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria:
- Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
- Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
- Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known active CNS metastases (brain and/or leptomeningeal metastases)
- Has significant cardiac disease
- Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
- Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1 Dose Escalation - 250 mg BID
Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 500 mg BID
PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 1000 mg BID
PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 1000 mg TID
PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 1 Dose Escalation - 2000 mg BID
PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 2 Dose Expansion - NSCLC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 2 Dose Expansion - ccRCC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Eksperimentel: Part 2 Dose Expansion - TMB-high solid tumors
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tidsramme: First dose to 35 days
|
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications. |
First dose to 35 days
|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tidsramme: Day 1 until 16 weeks after end of study treatment regimen
|
Proportion of participants with treatment-emergent adverse events and serious adverse events. |
Day 1 until 16 weeks after end of study treatment regimen
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsramme: Day 14, 0 to up to 12 hours
|
Maximum drug concentration (Cmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsramme: Day 14, 0 to up to 12 hours
|
Time to Cmax (Tmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tidsramme: Day 14, 0 to up to 12 hours
|
Area under the concentration-time curve (AUC0-τ) |
Day 14, 0 to up to 12 hours
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
Duration of response (DOR) for objective responders |
First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tidsramme: First dose to progression or death from any cause, whichever occurs first
|
Time on treatment (TOT) for objective responders |
First dose to progression or death from any cause, whichever occurs first
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Pliant Therapeutics Medical Monitor, Pliant Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Urothelialt karcinom
- Immunterapi
- Pembrolizumab
- Melanom
- Kolorektal cancer
- Endometriecancer
- Ikke-småcellet lungekræft (NSCLC)
- Cholangiocarcinom
- Avanceret kræft i faste tumorer
- Galdeblære
- Ovariekarcinom
- Tredobbelt negativ brystkræft (TNBC)
- Anal karcinom
- Clear Cell Nyrecellekarcinom (CCRCC)
- Galdevejscarcinom (BTC)
- Hoved- og halskræft (HNSCC)
- Tumorer med høj tumor mutationsbyrde (TMB)
- TMB-lave tumorer
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Patologiske processer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Lungesygdomme
- Neoplasmer i endokrine kirtler
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Tyktarmssygdomme
- Neoplastiske processer
- Lungeneoplasmer
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Hudsygdomme
- Brystsygdomme
- Urologiske neoplasmer
- Karcinom
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Nyre-neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Uterine neoplasmer
- Neuroendokrine tumorer
- Nevi og melanomer
- Neoplasmer i huden
- Brystneoplasmer
- Anus sygdomme
- Rektale neoplasmer
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Kolorektale neoplasmer
- Ovariale neoplasmer
- Neoplasma Metastase
- Karcinom, nyrecelle
- Karcinom, ikke-småcellet lunge
- Cholangiocarcinom
- Melanom
- Tredobbelt negative brystneoplasmer
- Endometriale neoplasmer
- Carcinom, overgangscelle
- Anus neoplasmer
- pembrolizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PLN-101095-ONC-101
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .